Lung Cancer最新文献

{"title":"Exercise medicine for individuals diagnosed with Lung Cancer: A systematic review and meta-analysis of health outcomes","authors":"Salvatore Ficarra ,&nbsp;Dong-Woo Kang ,&nbsp;Rebekah L. Wilson ,&nbsp;Paola Gonzalo-Encabo ,&nbsp;Cami N. Christopher ,&nbsp;Amber J. Normann ,&nbsp;Pedro Lopez ,&nbsp;Nemanja Lakićević ,&nbsp;Christina M. Dieli-Conwright","doi":"10.1016/j.lungcan.2025.108413","DOIUrl":"10.1016/j.lungcan.2025.108413","url":null,"abstract":"<div><div>Consensus exists regarding the need to provide exercise interventions to individuals diagnosed with lung cancer (LC). Exercise interventions for this populations usually include multidisciplinary approaches, making the attempt to understand the effects of exercise a real challenge. Therefore, we designed a systematic review to identify the effects of exercise interventions among individuals with a LC diagnosis.</div><div>Following the PRISMA guidelines, studies across 5 different databases were systematically screened. Eligible studies were randomised and non-randomised trials, including individuals with a LC diagnosis, administering exercise-only interventions. Three-level meta-analyses were performed for cardiorespiratory fitness, strength, physical function, anxiety, depression, and health-related quality of life. Differences between exercise types were also explored. The Cochrane Risk of Bias (RoB) II tool for randomised controlled trials and the RoB in non-randomised studies − of interventions were used to assess study quality.</div><div>A total of 36,304 records were screened and 13 studies, including 547 LC survivors, were considered eligible. Randomised and non-randomised trials were mainly judged as “some concern” and at “serious” RoB, respectively. Meta-analyses reported significant improvements on physical function among exercise groups compared to control (ES = 0.62; 95 % CI: 0.10 to 1.15; p = 0.03), and no significant changes for all other variables.</div><div>There is moderate evidence that exercise interventions appear to be an effective tool to improve physical function among individuals diagnosed with LC. Further studies are still needed to determine exercise prescription effectiveness on health outcomes, differences across exercise types and enhance individualized interventions.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"201 ","pages":"Article 108413"},"PeriodicalIF":4.5,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143445591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor concerning “Comparison of radiotherapy versus surgical resection following neoadjuvant chemoimmunotherapy in potentially resectable stage III non-small-cell lung cancer: A propensity score matching analysis”","authors":"Furkan Atasever,&nbsp;Sinem Nedime Sokucu,&nbsp;Celal Satici","doi":"10.1016/j.lungcan.2025.108423","DOIUrl":"10.1016/j.lungcan.2025.108423","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"201 ","pages":"Article 108423"},"PeriodicalIF":4.5,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143348203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials","authors":"D. Ross Camidge ,&nbsp;Shunichi Sugawara ,&nbsp;Masashi Kondo ,&nbsp;Hye Ryun Kim ,&nbsp;Myung-Ju Ahn ,&nbsp;James C.H. Yang ,&nbsp;Ji-Youn Han ,&nbsp;Maximilian J. Hochmair ,&nbsp;Ki Hyeong Lee ,&nbsp;Angelo Delmonte ,&nbsp;Kentarou Kudou ,&nbsp;Takayuki Asato ,&nbsp;Bradley Hupf ,&nbsp;Florin Vranceanu ,&nbsp;Robert J. Fram ,&nbsp;Yuichiro Ohe ,&nbsp;Sanjay Popat","doi":"10.1016/j.lungcan.2025.108424","DOIUrl":"10.1016/j.lungcan.2025.108424","url":null,"abstract":"<div><h3>Objectives</h3><div>Brigatinib approval as a first-line anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) for advanced <em>ALK</em>+ non-small cell lung cancer (NSCLC) is supported by results of a non-Japanese global phase 3 trial (ALTA-1L) and a separate phase 2 trial conducted in Japan (J-ALTA). To evaluate outcomes in a larger global patient population, we conducted an integrated analysis of pooled efficacy and safety data from ALTA-1L and J-ALTA.</div></div><div><h3>Materials and methods</h3><div>ALTA-1L (NCT02737501) and J-ALTA (NCT03410108) were open-label, multicenter studies of patients with advanced or metastatic <em>ALK</em>+ NSCLC. ALTA-1L and an expansion cohort of J-ALTA enrolled patients who were ALK TKI naive. Patients with stable or asymptomatic brain metastases were allowed. Brigatinib 180 mg was administered once daily following 7-day lead-in at 90 mg. Primary endpoints were blinded independent review committee (IRC)–assessed progression-free survival (PFS) in ALTA-1L and IRC-assessed 12-month PFS in the J-ALTA ALK TKI-naive cohort. Secondary endpoints included IRC-assessed objective response rate (ORR), duration of response (DOR), intracranial ORR, overall survival (OS), and safety.</div></div><div><h3>Results</h3><div>Overall, 169 patients were allocated to brigatinib in ALTA-1L (<em>n</em> = 137) or J-ALTA (<em>n</em> = 32). In the pooled population (median follow-up: 35.8 months), 34 % of patients were aged ≥65 years, 28 % had baseline brain metastases, and 26 % had received prior chemotherapy. Median PFS by IRC was 29.3 months (95 % CI: 23.9–44.7). Confirmed ORR was 79 % (95 % CI, 72 %–85 %). Median DOR was 38.1 months. Intracranial ORR was 66 % in patients with any brain metastases and 70 % in patients with measurable brain metastases. Three-year OS was 74 %. Grade 3/4 adverse events occurred in 74 % of patients, most commonly increased blood creatine phosphokinase (31 %), hypertension (18 %), and increased lipase (16 %).</div></div><div><h3>Conclusion</h3><div>Brigatinib demonstrated clinically meaningful systemic and intracranial efficacy in patients with ALK TKI-naive <em>ALK</em>+ NSCLC. Safety results were consistent with the known profile for brigatinib.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"201 ","pages":"Article 108424"},"PeriodicalIF":4.5,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143349515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brain metastases and mortality in patients with ALK + metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line targeted therapies: An observational cohort study","authors":"Dipesh Uprety ,&nbsp;Devin Abrahami ,&nbsp;Zachary A. Marcum ,&nbsp;Benjamin Li ,&nbsp;Angela Sang ,&nbsp;Matthew Davis ,&nbsp;Nada Rifi ,&nbsp;John M. Kelton ,&nbsp;Krishnan Ramaswamy ,&nbsp;Parag Sanghvi ,&nbsp;Lyudmila Bazhenova","doi":"10.1016/j.lungcan.2025.108436","DOIUrl":"10.1016/j.lungcan.2025.108436","url":null,"abstract":"<div><h3>Background</h3><div>Brain metastases (BM) are common in patients with ALK + metastatic non-small cell lung cancer (mNSCLC). Limited contemporary real-world evidence exists on the burden of BM in these patients. This study estimated the cumulative incidence of BM in patients with ALK + mNSCLC treated with second-generation ALK tyrosine kinase inhibitors (TKI) as first-line (1L) targeted therapies and assessed the association between BM and mortality.</div></div><div><h3>Materials and Methods</h3><div>Using a 100 % sample of Medicare fee-for-service and Advantage beneficiaries from 2017 to 2022, patients &gt; 65 years with ALK + mNSCLC (index date = 1L alectinib/brigatinib following lung cancer diagnosis) were identified. The cumulative incidence of BM was calculated, accounting for competing risk of death, overall and by age and race/ethnicity. To assess the association between BM and death, a time-varying Cox proportional hazards model compared the risk of death in those with incident, and baseline BM, separately, to those without BM, adjusting for confounders.</div></div><div><h3>Results</h3><div>In 1040 patients, 289 (28 %) had baseline BM. In 751 patients without baseline BM, the cumulative incidence of BM was 20 % after 5 years. After 4 years, the cumulative incidence of BM was highest in patients ≥ 85 years (25 %) and in non-White patients (23 %). Patients with incident BM had 2.6 times the risk of mortality compared to patients without BM (hazard ratio (HR): 2.59, 95 % confidence interval (CI): 1.98–3.38), while patients with baseline BM had 1.5 times the risk of mortality compared to patients without BM (HR: 1.46, 95 % CI: 1.20–1.77).</div></div><div><h3>Conclusions</h3><div>Patients with ALK + mNSCLC treated with second-generation ALK TKIs as 1L targeted therapies faced a high burden of BM. Incident BM were associated with increased mortality risk to a greater extent than baseline BM. Efforts are needed to provide safe and efficacious approaches to prevention and treatment of BM, including additional monitoring as required, in patients with ALK + mNSCLC.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"201 ","pages":"Article 108436"},"PeriodicalIF":4.5,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143395555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with PD-L1 tumor proportion score ≥50 %: A multicenter observational study","authors":"Yuichi Tambo ,&nbsp;Takashi Sone ,&nbsp;Koichi Nishi ,&nbsp;Kazuhiko Shibata ,&nbsp;Toshiyuki Kita ,&nbsp;Tomoyuki Araya ,&nbsp;Hiroki Shirasaki ,&nbsp;Takahiro Shimizu ,&nbsp;Taro Yoneda ,&nbsp;Hiroki Matsuoka ,&nbsp;Shigeki Nanjo ,&nbsp;Hayato Koba ,&nbsp;Nanao Terada ,&nbsp;Tsukasa Ueda ,&nbsp;Shunichi Nomura ,&nbsp;Yuya Murase ,&nbsp;Seiji Yano","doi":"10.1016/j.lungcan.2025.108422","DOIUrl":"10.1016/j.lungcan.2025.108422","url":null,"abstract":"<div><h3>Introduction</h3><div>Use of pembrolizumab as first-line treatment in patients with non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥ 50 % was approved in Japan 5 years ago. We investigated the long-term efficacy and safety of this treatment in a real-world setting.</div></div><div><h3>Methods</h3><div>This multicenter observational study enrolled 95 consecutive cases of histologically diagnosed advanced or recurrent NSCLC with a PD-L1 TPS score ≥ 50 %, who received pembrolizumab as first-line treatment between February 2017 and December 2018. Clinical data were collected from electronic medical records. PD-L1 TPS scores were assessed immunohistochemically, using the 22C3 antibody.</div></div><div><h3>Results</h3><div>The median follow-up period was 71.1 months. The median progression-free survival (PFS) was 6.9 months (95 % confidence interval [CI]; 4.7–9.1 months), and the 2-, 3-, and 5-year PFS rates were 24.9 %, 19.3 %, and 14.2 %, respectively. The median overall survival (OS) was 19.1 months (95 %CI; 13.3–24.9 months). The 2-, 3-, and 5-year OS rates were 42.7 %, 33.9 %, and 24.8 %, respectively. On multivariate analysis, histology (squamous vs. non-squamous cell carcinoma; hazard ratio [HR] 2.23, 95 %CI 1.40–3.89, p = 0.001) and number of metastatic sites (&lt; 3 vs. ≥ 3; HR 4.65 95 %CI 2.51–8.62, p &lt; 0.001) independently affected long-term survival. Immune-related adverse events occurred in 43 cases (45.3 %; 20 [21.0 %] Grade ≥ 3).</div></div><div><h3>Conclusion</h3><div>The real-world 5-year survival rate of NSCLC cases with PD-L1 ≥ 50 % treated with first-line pembrolizumab was comparable to that in a clinical trial. Histological type and number of metastatic sites influenced long-term and 5-year survival.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"201 ","pages":"Article 108422"},"PeriodicalIF":4.5,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143395978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual onsets of small cell lung cancer with contrasting neuroendocrine features and immune microenvironments: A case report","authors":"Toshiyuki Sumi ,&nbsp;Taiki Ishigooka ,&nbsp;Keigo Matsuura ,&nbsp;Takumi Ikeda ,&nbsp;Yuichi Yamada ,&nbsp;Naoki Shijubou ,&nbsp;Terufumi Kubo ,&nbsp;Hirofumi Chiba","doi":"10.1016/j.lungcan.2025.108420","DOIUrl":"10.1016/j.lungcan.2025.108420","url":null,"abstract":"<div><div>Small cell lung cancer (SCLC) is an aggressive malignancy with a poor prognosis and limited therapeutic options. Immune checkpoint inhibitors (ICIs) offer modest survival benefits; however, their efficacy is inconsistent, and only a few reliable biomarkers are available for guiding treatment. The molecular subtypes of SCLC, defined by transcription factor expression (SCLC-A, SCLC-N, SCLC-P, and SCLC-Y), exhibit distinct therapeutic vulnerabilities. Among these, the SCLC-I subtype, characterized by low neuroendocrine differentiation and high immune activity, is associated with an improved response to ICIs. However, the implications of the subtype transitions during disease progression remain unclear. Here, we describe the case of a patient in their 60 s who developed SCLC twice, presenting with distinct neuroendocrine features and immune profiles. The initial tumor, classified as SCLC-I, exhibited significant CD8 + T-cell infiltration and negative ASCL1/NEUROD1 expression, which correlated with a prolonged atezolizumab response. Three years later, a newly developed tumor in the contralateral lung displayed SCLC-A features, with ASCL1/NEUROD1 positivity and an absence of CD8 + infiltration, resulting in limited durvalumab efficacy. This report highlights the dynamic nature of SCLC and the importance of histopathological evaluation for guiding treatment. Larger studies are needed to validate the generalizability of these findings and explore biomarkers for diagnostic strategies.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"201 ","pages":"Article 108420"},"PeriodicalIF":4.5,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143275640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to Editor-in-Chief","authors":"Mariano Provencio,&nbsp;Bartomeu Massutí,&nbsp;Florentino Hernando-Trancho","doi":"10.1016/j.lungcan.2025.108419","DOIUrl":"10.1016/j.lungcan.2025.108419","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"201 ","pages":"Article 108419"},"PeriodicalIF":4.5,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143275641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mitigation of decline with virtual exercise with lung cancer (MoVE with lung cancer) − A promising approach to enhance physiological strength, improve body composition, and build upon current evidence","authors":"Ying Wang ,&nbsp;Rafael A. Fujita ,&nbsp;Natalie Fujisawa ,&nbsp;Janessa Laskin ,&nbsp;Pat Camp ,&nbsp;Sarah Yeo ,&nbsp;Gillian V.H. Smith ,&nbsp;Kendra Zadravec ,&nbsp;Kelly Mackenzie ,&nbsp;Kristin L. Campbell","doi":"10.1016/j.lungcan.2025.108418","DOIUrl":"10.1016/j.lungcan.2025.108418","url":null,"abstract":"<div><h3>Introduction</h3><div>Exercise can mitigate declines in physical function for patients with cancer, but in-person exercise programs for patients with advanced lung cancer often face low recruitment and retention. This prospective study assessed the feasibility of virtual exercise for patients with advanced lung cancer.</div></div><div><h3>Methods</h3><div>Mitigation of decline with Virtual Exercise (MoVE) with Lung Cancer was a prospective, single-arm, feasibility study. Patients with advanced lung cancer undergoing systemic therapy in British Columbia, Canada participated in a 12-week group exercise program delivered twice weekly via Zoom. Feasibility measures included accrual, recruitment rate, attendance, adherence, attrition, adverse events, and group belongingness. Efficacy was assessed via effect on physical function, cardiovascular fitness, body composition, and quality of life (QoL).</div></div><div><h3>Results</h3><div>Twenty-seven patients were enrolled (median age = 66 years). Most had adenocarcinoma (92 %) and were on targeted therapy (73 %). Recruitment rate was 61 %, attrition 4 %, attendance 87 %, and adherence 96 %. Significant improvements were seen in gait speed (Z = 2.759, p = 0.006), 30-second chair stand (Z = 3.810, p &lt; 0.001), 30-second bicep curl (Z = 4.209, p &lt; 0.001), 8-foot timed up and go (Z = −3.148, p = 0.002), six minute walk test (Z = 3.124, p = 0.002), and QoL (FACT-G post hoc p = 0.005). Participants’ skeletal muscle index increased by 0.9 cm² (p = 0.033). Participant satisfaction was high (4.6/5).</div></div><div><h3>Conclusions</h3><div>A 12-week virtually supervised exercise program for patients with advanced lung cancer showed high attendance and adherence, with significant improvements in physical function and positive participant feedback. These results demonstrate that physical function can be maintained or improved during systemic treatments for advanced lung cancer.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"201 ","pages":"Article 108418"},"PeriodicalIF":4.5,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143275547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"15 Use of a virtual platform in screening lung cancer referrals with low suspicion on chest x-ray","authors":"Reid Phil","doi":"10.1016/j.lungcan.2025.108126","DOIUrl":"10.1016/j.lungcan.2025.108126","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"200 ","pages":"Article 108126"},"PeriodicalIF":4.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"30 Creating a single queue for referrals for Image Guided lung biopsy in Greater Manchester: an overview of the process and initial results from the pilot study","authors":"Duerden Rebecca ,&nbsp;Hulme Sarah ,&nbsp;Galligan- Dawson Lisa ,&nbsp;Balata Haval ,&nbsp;Brown Louise ,&nbsp;Nasser Rehan ,&nbsp;Annamalaisammy Rajesh ,&nbsp;Lama Ashish ,&nbsp;Lay James ,&nbsp;Razzaq Rubeena ,&nbsp;Sharman Anna ,&nbsp;Upile Sandeep ,&nbsp;Walsham Anna ,&nbsp;Whittaker James ,&nbsp;Williams Marc ,&nbsp;Evison Matthew","doi":"10.1016/j.lungcan.2025.108141","DOIUrl":"10.1016/j.lungcan.2025.108141","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"200 ","pages":"Article 108141"},"PeriodicalIF":4.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143511916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}